ReviewFrontiers in medicine2021
Cefiderocol: An Overview of Its
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Rational Design of a Synthetic Galliphore for the Diagnostic Nuclear Imaging and Treatment of Bacterial Infections.Angewandte Chemie (International ed. in English) · 2026Article
- Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration.Journal of clinical microbiology · 2026Article
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Cefiderocol Comparative Resistance and Clinical Predictors in CRE-BSI: Data from an OXA-48-Endemic Region with Rising OXA-48/NDM Coproducers.Antibiotics (Basel, Switzerland) · 2025Article
- Evolution of β-Lactam Antibiotic Resistance inMicroorganisms · 2025Review
- Characterization ofAntibiotics (Basel, Switzerland) · 2025Article
- The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.BMC infectious diseases · 2024Article
- Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Microbiology spectrum · 2024Article
- Benzothiazole DNA gyrase inhibitors and their conjugates with siderophore mimics: design, synthesis and evaluation.RSC advances · 2024Article
- Extensively drug-resistantFrontiers in microbiology · 2024Article
- Article
- ConvergentEmerging microbes & infections · 2023Article
- Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.Scientific reports · 2023Article
- Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Novel Resistance Regions Carrying TnAntibiotics (Basel, Switzerland) · 2023Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Antibacterial spectrum of cefiderocol.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of multidrug-resistant (MDR) Gram-negative bacteria (GNB) infections has led to a global public health challenging due to the bacterial resistance and limited choices of antibiotics. Cefiderocol (CFDC), a novel siderophore cephalosporin possessed unique drug delivery systems and stability to β-lactamases, has the potential to become first-line therapy for most aggressive MDR Gram-negative pathogens infection. However, there have been reports of drug resistance in the course of using CFDC. This study provides an overview of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.